Insmed Inc (INSM)vsOmniAb Inc. (OABI)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
OABI
OmniAb Inc.
$1.67
-5.11%
HEALTHCARE · Cap: $254.82M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 3149% more annual revenue ($606.42M vs $18.67M). OABI leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
OABI
Avoid27
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : OABI
The strongest argument for OABI centers on Price/Book, Debt/Equity, Altman Z-Score.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : OABI
The primary concerns for OABI are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while OABI is a value play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
OABI generates stronger free cash flow (-6M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 27/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
OmniAb Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
OmniAb Inc. is an innovative biotechnology company specializing in the development of fully human therapeutic antibodies through its proprietary OmniAb platform. This advanced technology enables the efficient discovery and optimization of high-quality therapeutics aimed at addressing a wide array of diseases. With a strategic emphasis on collaborations and partnerships, OmniAb is committed to accelerating drug development processes and enhancing the availability of breakthrough treatments. Led by a skilled management team and supported by a robust pipeline, the company is poised to capitalize on the growing opportunities within the biopharmaceutical sector.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?